Encontrados 3 documentos, a visualizar página 1 de 1
Long-term effects of tafamidis for the treatment of transthyretin familial amyl...
Coelho, T.; Maia, L.; Martins-Silva, A.; Cruz, M.; Planté-Bordeneuve, V.; Suhr, O.; Conceição, I.; Schmidt, H.; Trigo, P.; Kelly, J.; Labaudinière, R.Tafamidis, a transthyretin (TTR) kinetic stabilizer, delayed neuropathic progression in patients with Val30Met TTR familial amyloid polyneuropathy (TTR-FAP) in an 18-month randomized controlled trial (study Fx-005). This 12-month, open-label extension study evaluated the long-term safety, tolerability, and efficacy of tafamidis 20 mg once daily in 86 patients who earlier received blinded treatment with tafamidi...
Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or am...
HIRSCH‐REINSHAGEN, V.; CHAN, J.Y.; WILKINSON, A.; TANAKA, T.; FAN, J.; OU, G.; MAIA, L.F.; SINGARAJA, R.R.; HAYDEN, M.R.; WELLINGTON, C.L.J Lipid Res. 2007 Apr;48(4):914-23. Epub 2007 Jan 18. Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or amyloid-beta peptide levels in vivo. Hirsch-Reinshagen V, Chan JY, Wilkinson A, Tanaka T, Fan J, Ou G, Maia LF, Singaraja RR, Hayden MR, Wellington CL. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. Abstract ABCA1-deficient mic...
The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloi...
HIRSCH‐REINSHAGEN, V.; MAIA, L.F.; BURGESS, B.L.; BLAIN, J.F.; NAUS, K.E.; MCISAAC, S.A.; PARKINSON, P.F.; CHAN, J.Y.; TANSLEY, G.H.; HAYDEN, M.R.J Biol Chem. 2005 Dec 30;280(52):43243-56. Epub 2005 Oct 5. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, Poirier J, Van Nostrand W, Wellington CL. Department of Pathology and Laboratory Medicine, Univers...
| Financiadores do RCAAP | |||||||
|
|
|
|
|
|
||